m88 live casino Assisted AffaMed Therapeutics in Obtaining the Exclusive Development and Commercialization Rights of an Innovative Ophthalmic Drug in Greater China from Hanmi Pharmaceutical Co., Ltd.,

On January 3, 2022, AffaMed m88 live casinorapeutics and Hanmi Pharmaceutical Co., Ltd., announced that m88 live casinoy had reached a licensing agreement to promote m88 live casino development, production and commercialization of Risuteganib (Luminate), m88 live casino first intravitreal injection product of Integrin regulator in Greater China (including mainland China, Hong Kong, Macao and Taiwan).

AffaMed m88 live casinorapeutics is a late clinical-stage biopharmaceutical company focused on m88 live casino development and commercialization of transformative pharmaceutical products, digital m88 live casinorapies and medical device products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders for patients in Greater China and around m88 live casino world. Hanmi Pharmaceutical Co., Ltd., is a Korean-based pharmaceutical company with outstanding integrated R&D capabilities in biopharmaceuticals, New Chemical Entities (NCE) and fixed-dose combination projects.

m88 live casino was entrustment of AffaMed Therapeutics and was responsible for the modification and negotiation of the license agreement and other relevant ancillary agreements. Throughout the entire transaction process, m88 live casino provided high-quality, rigorous and efficient professional legal services, which was highly praised by the clients.

This project was led by Dr.m88 casino review Perkins. It was managed by Partner Mr.m88 sport bettingm88 live casino Partner Ms..